ESMO and Apogenix Collaborate on “Recurrent Glioblastoma Management: Challenges and Opportunities” Colloquium
Apogenix, a biopharmaceutical company developing next generation immuno-oncology therapeutics, announced today that it will be supporting a colloquium titled “Recurrent Glioblastoma Management: Challenges and Opportunities” at this year’s ESMO Congress, held from September 27 to October 1 at the Fira Gran Via in Barcelona, Spain. The chairs and speakers – all international experts in the glioblastoma field – will discuss the current standard of care for recurrent glioblastoma, novel treatment approaches, the role and biological mechanisms of the CD95/CD95 ligand (Fas/Fas ligand) pathway, as well as the rationale and clinical results of CD95 ligand/Fas ligand inhibition.